{"name":"Antios Therapeutics, Inc","slug":"antios-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNYk5fUTdiZXJyZXNiS3ZQc1ZYRldqQ1BKQ2tEcVdqRlZ1U0o2dzNLSEwyU2o3czBDVnpKWC1aYnFJMVNUZ0hDZFRpS2trZGpzUGRJcXltYXoxYWdaLXhzems0VG1ObS1sRzdmUmJ1OFpnSHVwcXpCQXlvdVcxcjJOTWlVTHllcFZRWWItWGJneXI3cGdVb3lXS0RRRktkS0xYMGNqcTY2eXRWTHBTM0NrTGJvRjN6a2ctZWlKTzQyZFZMNWlTWDU1SzZINjh4bVdOVkUxMHhhSjAzX2QxZWMxUDM3MUxSbXVmdkJ2aFhZWGRKbU5IR19kVTN2WVJOSTZkOHpRWWdoVnFFTnNhaGc?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Trea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5BSlZRTkJjcFRSbG1GdV9ZVXNzeUIwcDRsTXJpWUwzaDMxSDhBYTJyUE9oV2NwSGJyYVZRS3pmMXVaRFIyZURSNFlDbmZ3S0IxeWtjUUZsNA?oc=5","date":"2024-04-03","type":"pipeline","source":"Market.us","summary":"Hepatitis D Market Size, Share | CAGR Of 3.34% - Market.us","headline":"Hepatitis D Market Size, Share | CAGR Of 3.34%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE8ySkR4ZndXbDZZVWxmT19JZnN3WlNYVVlsdmRYbGhhVmdveGZIRDg0RldhV3JiUmpORUVuTlU0WXlvT1g0SlVLdGUwZ0U1VjhpS29qSE9UZ0wwVUExbmRtRmphT0JrX0F5RjFZeQ?oc=5","date":"2023-10-31","type":"pipeline","source":"Fierce Biotech","summary":"UPDATED: The 2023 Biotech Graveyard - Fierce Biotech","headline":"UPDATED: The 2023 Biotech Graveyard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPVmZLWDh3UzRjTk5WU0JhcllnWTVNVFdmYkEtOWh3cjRTWDlLTzljUlJYaE5sbnVWcEUzelJXeXVrSk1ZNFR0aUI4R19QWk5EZzdNeTF4WHpfV0F0TlJoajJ6d1JvZzR6OGh1cS02U3VsRUlDMTllWEJhUW1hMzBVaVVjZ3Y4dXpfSFRLT0NXRlF3ek5aTFZ2bi1QRHRJY0VwMlBFeQ?oc=5","date":"2023-09-22","type":"regulatory","source":"Fierce Biotech","summary":"Hep B biotech Antios closed after FDA hold proved insurmountable - Fierce Biotech","headline":"Hep B biotech Antios closed after FDA hold proved insurmountable","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE81SXNoMjRKVmRuWldjQ1RCdTk3Tlg5UnlSU3dsNGpmZnExdEY0NkphcGpyQi11dXFQVkE4MG5HSG9WVndtSTlWOVJUX1k4dGtmeGZYODJpLUUwNzhORlZDWFlERQ?oc=5","date":"2023-04-13","type":"pipeline","source":"Precedence Research","summary":"Hepatitis D Market Size to Hit USD 1,092.71 Million by 2035 - Precedence Research","headline":"Hepatitis D Market Size to Hit USD 1,092.71 Million by 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxObU9jMGVibENoV0hhX2xWRk5wbU12OFJhUVU5a1cweWxYeDdTa0lQLVZGT3VaRnBVeUFGbG5KS3RtNFItZlJZbFJTQjVWaU5rU1FBNC0tY3pzLXAySXZSUVd5SWk2emd6SXI4MDBVQWtBSGpDa0hlblJxLTBxYWh3Zm1QNl9SZ2gzdGFGV3JERHl4TXhNWDVBQnBjcHBpdW5aTGxUYV94MThmeHpwdlFsRWE2ejh3dE1nenUyWVBOclItYlhub3BMWWNEb01uWC14ekxyWHVMTWZDRzlrVXJOYnRDOWxkTVE4ZGc?oc=5","date":"2021-11-03","type":"pipeline","source":"PR Newswire","summary":"Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV - PR Newswire","headline":"Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNR3JvNmFDOERpY24tTVBLaVNDSjVxaURScVQ2VEtGWUpRelNnMGUwS1J2bUpnT3BYX1lJblRpanJYQ2hwN1RYUGtMN0tDSkVhem15cGphNm9HX2VlUGVUQjVlVjJIaUFmclczR2FPMGx4UmpjWlJYV1lPUFktVmhhYlp2ZHFKMDZPdUxDY0lsNDZxTHgxa1ZQZDNVOWZNc0F3MHA5WllUbmVrRkE1d2FDUDNIMHRZZGVzNmlnclY3bENfc3Rocmo1UHpCVXlSdw?oc=5","date":"2021-04-12","type":"pipeline","source":"GlobeNewswire","summary":"Antios Therapeutics Raises $96 Million in a Series B Financing - GlobeNewswire","headline":"Antios Therapeutics Raises $96 Million in a Series B Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOYzlBdkNCRGZWXzZvUlQ5b3JBV1cycFRFZERtY3FhYkdxMUNpbTJ6Y2tXZ19tN1BKWE43Vmp6RkJyVWFyR3lxdVZndFBsRUFESGZNNGxJNnlqck9CaVdNWExrQWFBZXJHZVNhXzFwOXZUY29lQkJyYWZ2Y1FvUjUyRVBTMlc4MjNTQlFSNTB3TWFxOTRtX2x6NDY4LVdtTURFNlE?oc=5","date":"2020-12-04","type":"pipeline","source":"The Business Journals","summary":"Biopharmaceutical company Antios Therapeutics names CEO successor - The Business Journals","headline":"Biopharmaceutical company Antios Therapeutics names CEO successor","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}